Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 37 citing articles:

PINK1-PRKN mediated mitophagy: differences between in vitro and in vivo models
Rui Han, Yanting Liu, Shihua Li, et al.
Autophagy (2022) Vol. 19, Iss. 5, pp. 1396-1405
Open Access | Times Cited: 84
New pathogenic insights from large animal models of neurodegenerative diseases
Peng Yin, Shihua Li, Xiao‐Jiang Li, et al.
Protein & Cell (2022) Vol. 13, Iss. 10, pp. 707-720
Open Access | Times Cited: 46
CRISPR/Cas9 Genome Editing for Tissue‐Specific In Vivo Targeting: Nanomaterials and Translational Perspective
Deepak Kumar Sahel, Lalitkumar K. Vora, Aishwarya Saraswat, et al.
Advanced Science (2023) Vol. 10, Iss. 19
Open Access | Times Cited: 34
Application and perspective of CRISPR/Cas9 genome editing technology in human diseases modeling and gene therapy
Manling Zhang, Hongbin Li, Yong Jin
Frontiers in Genetics (2024) Vol. 15
Open Access | Times Cited: 14
Genetically modified non-human primate models for research on neurodegenerative diseases
Ming-Tian Pan, Han Zhang, Xiao‐Jiang Li, et al.
动物学研究 (2024) Vol. 45, Iss. 2, pp. 263-274
Open Access | Times Cited: 10
PINK1 kinase dysfunction triggers neurodegeneration in the primate brain without impacting mitochondrial homeostasis
Weili Yang, Xiangyu Guo, Zhuchi Tu, et al.
Protein & Cell (2021) Vol. 13, Iss. 1, pp. 26-46
Open Access | Times Cited: 49
CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson’s Disease
Mujeeb Ur Rahman, Muhammad Bilal, Junaid Ali Shah, et al.
Pharmaceutics (2022) Vol. 14, Iss. 6, pp. 1252-1252
Open Access | Times Cited: 35
Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders
Laura M. De Plano, Giovanna Calabrese, Sabrina Conoci, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8714-8714
Open Access | Times Cited: 29
CRISPR-Cas System: The Current and Emerging Translational Landscape
Narendranath Bhokisham, Ethan Laudermilch, Lindsay L. Traeger, et al.
Cells (2023) Vol. 12, Iss. 8, pp. 1103-1103
Open Access | Times Cited: 17
Genetically modified large animal models for investigating neurodegenerative diseases
Weili Yang, Xiusheng Chen, Shihua Li, et al.
Cell & Bioscience (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 29
An update on mammalian and non-mammalian animal models for biomarker development in neurodegenerative disorders
Ribhav Mishra, Arun Upadhyay
Cellular and Molecular Life Sciences (2025) Vol. 82, Iss. 1
Open Access
Advanced gene therapy in Parkinson’s disease through innovations in drug delivery systems
Nguyễn Phương Thảo, Thuy-vi Nguyen, Soyeun Park
Journal of Pharmaceutical Investigation (2025)
Closed Access
Application of CRISPR/Cas9 System in Establishing Large Animal Models
Yingqi Lin, Jun Li, Caijuan Li, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 18
MED13 and glycolysis are conserved modifiers of α-synuclein-associated neurodegeneration
Mengda Ren, Ying Yang, Kelsey Hwee Yee Heng, et al.
Cell Reports (2022) Vol. 41, Iss. 12, pp. 111852-111852
Open Access | Times Cited: 16
A booming field of large animal model research
Xiao‐Jiang Li, Liangxue Lai
动物学研究 (2024) Vol. 45, Iss. 2, pp. 311-313
Open Access | Times Cited: 3
Mitochondrial-Dependent and Independent Functions of PINK1
Xiusheng Chen, Qi Wang, Shihua Li, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 14
Outlook of PINK1/Parkin signaling in molecular etiology of Parkinson’s disease, with insights into <i>Pink1</i> knockout models
Zhangting Wang, See-Wing Chan, Hui Zhao, et al.
动物学研究 (2023) Vol. 44, Iss. 3, pp. 559-576
Open Access | Times Cited: 8
Parkinson’s Disease: A Tale of Many Players
Ernest K. J. Pauwels, Gerard J. Boer
Medical Principles and Practice (2023) Vol. 32, Iss. 3, pp. 155-165
Open Access | Times Cited: 6
Development of CRISPR Cas9, spin-off technologies and their application in model construction and potential therapeutic methods of Parkinson’s disease
Jiangbo Qu, Na Liu, Lu Gao, et al.
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 6
Modeling neurodegenerative diseases using non-human primates: advances and challenges
Bang Li, Dajian He, Xiao‐Jiang Li, et al.
Ageing and Neurodegenerative Diseases (2022) Vol. 2, Iss. 3, pp. 12-12
Open Access | Times Cited: 9
Induction of Anxiety-Like Phenotypes by Knockdown of Cannabinoid Type-1 Receptors in the Amygdala of Marmosets
Lin Zhu, Di Zheng, Rui Li, et al.
Neuroscience Bulletin (2023) Vol. 39, Iss. 11, pp. 1669-1682
Open Access | Times Cited: 5
Update on Nonhuman Primate Models of Brain Disease and Related Research Tools
Nan Qiao, Lizhen Ma, Yi Zhang, et al.
Biomedicines (2023) Vol. 11, Iss. 9, pp. 2516-2516
Open Access | Times Cited: 5
Visualizing advances in the future of primate neuroscience research
Peter Janssen, Tadashi Isa, José L. Lanciego, et al.
Current Research in Neurobiology (2022) Vol. 4, pp. 100064-100064
Open Access | Times Cited: 8
In vivo and ex vivo gene therapy for neurodegenerative diseases: a promise for disease modification
Pouyan Ebrahimi, Elham Davoudi, Razieh Sadeghian, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 10, pp. 7501-7530
Closed Access | Times Cited: 1
Emerging Gene-editing nano-therapeutics for Cancer
Najma Nujoom, Manzoor Koyakutty, Lalitha Biswas, et al.
Heliyon (2024) Vol. 10, Iss. 21, pp. e39323-e39323
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top